Libtayo® (cemiplimab) phase 3 data in the adjuvant treatment of post-surgical high-risk cutaneous squamous cell carcinoma (cscc) have potential to be practice-changing

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p

REGN Ratings Summary

REGN Quant Ranking